Improving the immune response of stem cells to treat graft-versus-host disease.
Mechanical programming to enhance the immunosuppressive function of mesenchymal stem cells for the treatment of graft-versus-host disease.
This study is looking at ways to make special stem cells better at helping people with graft-versus-host disease (GvHD) by creating a more natural environment for them to grow, which could lead to improved treatments for patients who have had stem cell transplants.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Johns Hopkins University NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project ID | NIH-10905160 on NIH RePORTER |
What this research studies
This research focuses on enhancing the immunosuppressive abilities of mesenchymal stem cells (MSCs) to better treat graft-versus-host disease (GvHD). The approach involves optimizing the mechanical environment in which these stem cells are produced, as this can significantly influence their effectiveness. By using a specialized hydrogel system that mimics the natural conditions of the body, the researchers aim to create MSCs that are more potent in regulating immune responses. This could lead to more effective therapies for patients suffering from GvHD, a serious complication often seen in patients undergoing stem cell transplants.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients who have undergone stem cell transplants and are at risk of developing graft-versus-host disease.
Not a fit: Patients who do not have graft-versus-host disease or are not undergoing stem cell transplants may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with graft-versus-host disease, improving their recovery and quality of life.
How similar studies have performed: Previous research has shown promise in using mechanical cues to enhance stem cell therapies, indicating that this approach may lead to significant advancements in treatment.
Where this research is happening
Baltimore, United States
- Johns Hopkins University — Baltimore, United States (Active)
Researchers
- Principal investigator: Gu, Luo — Johns Hopkins University
- Study coordinator: Gu, Luo
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.